CN114146032A - 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 - Google Patents
一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN114146032A CN114146032A CN202111458306.8A CN202111458306A CN114146032A CN 114146032 A CN114146032 A CN 114146032A CN 202111458306 A CN202111458306 A CN 202111458306A CN 114146032 A CN114146032 A CN 114146032A
- Authority
- CN
- China
- Prior art keywords
- hydrangea macrophylla
- extract
- composition
- solvent
- hydrangea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000014486 Hydrangea macrophylla Nutrition 0.000 title claims abstract description 64
- 244000267823 Hydrangea macrophylla Species 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000000605 extraction Methods 0.000 title description 2
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 239000002904 solvent Substances 0.000 claims abstract description 19
- 239000004472 Lysine Substances 0.000 claims abstract description 18
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000004900 autophagic degradation Effects 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 239000004615 ingredient Substances 0.000 claims abstract description 13
- 230000028327 secretion Effects 0.000 claims abstract description 12
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 230000008591 skin barrier function Effects 0.000 claims description 8
- 239000008367 deionised water Substances 0.000 claims description 7
- 229910021641 deionized water Inorganic materials 0.000 claims description 7
- 241001092080 Hydrangea Species 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- -1 polydimethylsiloxane Polymers 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 229940099549 polyglycerin-3 Drugs 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 229940104261 taurate Drugs 0.000 claims description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 22
- 230000037394 skin elasticity Effects 0.000 abstract description 7
- 210000002510 keratinocyte Anatomy 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 239000002085 irritant Substances 0.000 abstract description 2
- 231100000021 irritant Toxicity 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 102000000018 Chemokine CCL2 Human genes 0.000 description 7
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000036572 transepidermal water loss Effects 0.000 description 5
- 210000004957 autophagosome Anatomy 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- AWFYPPSBLUWMFQ-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=C2 AWFYPPSBLUWMFQ-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 101150090916 ATG3 gene Proteins 0.000 description 1
- 101150102163 ATG7 gene Proteins 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 108700013048 CCL2 Proteins 0.000 description 1
- 101710146188 Ceramide synthase 3 Proteins 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 241000134970 Cornales Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100028314 Filaggrin Human genes 0.000 description 1
- 101710088660 Filaggrin Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000004642 autophagic pathway Effects 0.000 description 1
- 230000005033 autophagosome formation Effects 0.000 description 1
- 230000007320 autophagy mechanism Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- MKYNHKOAYQRSBD-UHFFFAOYSA-N dioxouranium;nitric acid Chemical compound O=[U]=O.O[N+]([O-])=O.O[N+]([O-])=O MKYNHKOAYQRSBD-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
Abstract
本发明属于化妆品技术领域,公开了一种包含粗齿绣球叶提取物的组合物及其制备方法和应用。本发明包含粗齿绣球叶提取物的组合物包含活性成分、促渗成分和溶剂,其中,所述活性成分和促渗成分的质量比为0.1‑20:2‑3,所述活性成分中包含粗齿绣球叶提取物和赖氨酸。本发明所述粗齿绣球提取物和赖氨酸组合可以发挥协同作用,温和无刺激,通过诱导细胞自噬、减少细胞炎症因子分泌,促进角质细胞分化,提升皮肤弹力。
Description
技术领域
本发明涉及化妆品技术领域,具体是涉及一种包含粗齿绣球叶提取物的组合物及其制备方法和应用。
背景技术
具有美好寓意的花朵深受人们的喜爱,比如:芍药、牡丹、桃花、绣球花等。其中,绣球花又被称为“八仙花”,花型丰满,寓意“希望、健康、美满、团园”,是常见的盆栽观赏花木。随着社会的进步、科学技术的发展以及生活水平的提高,人们追求天然、追求绿色、追求健康与安全的意识日益增强,绿色化以及功能性的化妆品越来越受人们的青睐,因此复合植物提取物在化妆品中的应用也越来越广泛,应用的品种也越来越多。然而,对于粗齿绣球提取物在皮肤上的作用的研究较少。
中国专利申请CN111315353公开了包含粗齿绣球提取物作为有效成分的因紫外线引起的人表皮细胞及真皮细胞损伤改善用组合物,该发明声称这种组合物不仅可恢复人表皮细胞及真皮细胞中的因UV B引起的细胞损伤,而且增加透明质酸的分泌,并抑制MMP 1的分泌,由此可改善因UV B引起的细胞损伤。中国专利申请CN111315354中描述一种含有粗齿绣球提取物和陈皮提取物的化妆料组合物,所述化妆料组合物包含含有高浓度的绣球酚及特定成分的粗齿绣球提取物,从而对皮肤抗老化及保湿具有极大改善的效果。但是,目前并未有研究进行粗齿绣球提取物在通过细胞自噬途径改善肌肤机理方面的基础研究,也没有相关的产品。
发明内容
本发明为了克服上述背景技术的不足,进行了粗齿绣球提取物诱导细胞自噬、减少细胞炎症因子分泌、改善皮肤弹性方面的研究,提出一种包含粗齿绣球叶提取物的组合物及其制备方法和应用。
为达到本发明的目的,本发明包含粗齿绣球叶提取物的组合物包含活性成分、促渗成分和溶剂,其中,所述活性成分和促渗成分的质量比为0.1-20:2-3,所述活性成分中包含粗齿绣球叶提取物和赖氨酸。
进一步地,在本发明的一些实施例中,所述粗齿绣球叶提取物的制备方法为:将粗齿绣球叶清洗分拣,干燥,加入2-3倍质量的溶剂超声粉碎匀浆,过滤,滤液浓缩至三分之一至五分之一即得。
进一步地,在本发明的一些实施例中,所述活性成分和促渗成分的质量比为0.1-10:2-3。
进一步地,在本发明的一些实施例中,所述活性成分中粗齿绣球叶提取物和赖氨酸的质量比为1-10:0.1-0.5;优选2-10:0.1-0.5;更优选5-10:0.2-0.5。
进一步地,在本发明的一些实施例中,所述促渗成分为1,2-戊二醇、1,2-己二醇和卵磷脂中的一种或多种。
进一步地,在本发明的一些实施例中,所述溶剂为去离子水、乙醇、丙二醇、丁二醇、双丙甘醇和甘油中的一种或多种。
另一方面,本发明还提供了一种前述包含粗齿绣球叶提取物的组合物的制备方法,所述方法包含以下步骤:
(1)将粗齿绣球叶清洗分拣,干燥,加入2-3倍溶剂超声粉碎匀浆,过滤,超声时间30-60min,频率40-80Hz,次数2-3次,合并滤液浓缩至五分之一至三分之一备用;
(2)在步骤(1)所得粗齿绣球叶提取物中加入赖氨酸(粗齿绣球叶提取物和赖氨酸合称为活性成分)、促渗成分和溶剂,加热搅拌均匀,过滤,再加入余量溶剂,搅拌均匀得到组合物。
进一步地,在本发明的一些实施例中,所述步骤(2)中活性成分、促渗成分与溶剂的质量比为0.1-20:2-3:77-97。
进一步地,在本发明的一些实施例中,所述步骤(2)中加热搅拌前加入的溶剂和余量溶剂的质量比为35-45:32-62。
进一步地,在本发明的一些实施例中,所述步骤(1)中干燥为冷冻干燥。
进一步地,在本发明的一些实施例中,所述步骤(2)中过滤是用膜孔径为0.15-0.25微米的滤膜过滤。
再一方面,本发明还提供了一种前述包含粗齿绣球叶提取物的组合物的应用,所述应用为将包含粗齿绣球叶提取物的组合物用于制备诱导细胞自噬、降低/治疗炎症反应类病症的化妆品或药物。
进一步地,在本发明的一些实施例中,所述化妆品或药物为减少炎症因子分泌修复肌肤屏障的化妆品或药物。
更进一步地,在本发明的一些实施例中,所述化妆品为水剂、乳剂、喷雾、膏霜、面膜、洁面泡沫、洁面慕斯、油液、粉饼、眼影或粉底液。
再一方面,本发明还提供了一种包含前述粗齿绣球叶提取物的精华乳,所述精华乳中还包含聚甘油-3二硬脂酸酯、硬脂酸乙基己酯、聚二甲基硅氧烷、硬脂酸、甘油、水、黄原胶、对羟基苯乙酮和丙烯酰二甲基牛磺酸铵/VP共聚物。
与现有技术相比,本发明具有以下优点和有益效果:
本发明通过对于粗齿绣球叶提取物影响皮肤作用机制的研究,发现了所述包含粗齿绣球叶提取物的组合物,该组合物可诱导细胞自噬清除受损细胞、抑制细胞炎症因子分泌减少皮肤慢性炎症反应发生,通过提高紧密连接蛋白和丝聚蛋白的合成、促进角质细胞分化修复受损的皮肤屏障,增强皮肤弹力。特别地,本发明所述粗齿绣球提取物和赖氨酸组合可以发挥协同作用,温和无刺激,通过诱导细胞自噬、减少细胞炎症因子分泌,促进角质细胞分化,提升皮肤弹力,提高基因神经酰胺合酶-3的表达修复受损的肌肤屏障。
附图说明
图1是本发明实施例1-6、对比例1的LC3II蛋白的表达率(%);
图2是本发明实施例4对于PGE-2分泌水平的影响;
图3是本发明实施例4对于MCP-1分泌水平的影响;
图4是使用本发明产品四周经表皮水分流失TEWL的变化;
图5为使用本发明产品四周皮肤血红素含量的变化;
图6为使用本发明产品四周皮肤回弹比R2的变化。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合附图及实施例,对本发明进行进一步详细说明。本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。应当理解,以下描述仅仅用以解释本发明,并不用于限定本发明。
本文中所用的术语“包含”、“包括”、“具有”、“含有”或其任何其它变形,意在覆盖非排它性的包括。例如,包含所列要素的组合物、步骤、方法、制品或装置不必仅限于那些要素,而是可以包括未明确列出的其它要素或此种组合物、步骤、方法、制品或装置所固有的要素。
当量、浓度、或者其它值或参数以范围、优选范围、或一系列上限优选值和下限优选值限定的范围表示时,这应当被理解为具体公开了由任何范围上限或优选值与任何范围下限或优选值的任一配对所形成的所有范围,而不论该范围是否单独公开了。例如,当公开了范围“1至5”时,所描述的范围应被解释为包括范围“1至4”、“1至3”、“1至2”、“1至2和4至5”、“1至3和5”等。当数值范围在本文中被描述时,除非另外说明,否则该范围意图包括其端值和在该范围内的所有整数和分数。
本发明要素或组分前的不定冠词“一种”和“一个”对要素或组分的数量要求(即出现次数)无限制性。因此“一个”或“一种”应被解读为包括一个或至少一个,并且单数形式的要素或组分也包括复数形式,除非所述数量明显只指单数形式。
此外,下面所描述的术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不是必须针对相同的实施例或示例。而且,本发明各个实施方式中所涉及到的技术特征只要彼此之间未构成冲突就可以相互组合。
实施例1
一种包含粗齿绣球叶提取物的组合物,制备工艺如下:
(1)将粗齿绣球叶清洗分拣干净,冷冻干燥,加入2-3倍去离子水粉碎匀浆,超声频率为65Hz,时间45min,重复2-3次,合并滤液浓缩至三分之一得到粗齿绣球叶提取物备用;
(2)将粗齿绣球叶提取物加入赖氨酸(粗齿绣球叶提取物和赖氨酸合称为活性成分)、2重量份1,2-己二醇和去离子水(活性成分、1,2-己二醇与去离子水的质量比为6:2:40)中,加热搅拌均匀,0.2微米孔径过滤膜过滤,补足余量去离子水至100重量份,搅拌均匀得到组合物。
表1所示为实施例1-6及对比例1-2中各组合物中粗齿绣球叶提取物和赖氨酸的组成比例。根据表1的比例并采用上述方法制备各实施例及对比例的组合物,并对所得组合物进行功效测试。
表1实施例1-6及对比例1-2中各组合物组成
组别 | 粗齿绣球叶提取物:赖氨酸(质量比) |
实施例1 | 1:0.1 |
实施例2 | 2:0.1 |
实施例3 | 5:0.1 |
实施例4 | 5:0.2 |
实施例5 | 5:0.5 |
实施例6 | 10:0.5 |
对比例1 | 0:0 |
对比例2 | 1:0 |
细胞毒性评价实例
组合物细胞毒性评价:MTT assay是通过对活细胞数进行测定,在检测细胞毒性或细胞增殖时广泛使用的实验方法,其检测原理为活细胞线粒体中的琥珀酸脱氢酶能使水溶性的黄色盐MTT(3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐)还原为水不溶性的蓝色的甲臜,并沉积在细胞中,而死细胞无此功能。生成的结晶甲臜一般加入DMSO(二甲亚砜),溶解后测定吸光度。具体的实验方法是在96多孔板中按照1X104个/孔的密度接种含有10%牛血清的DMEM培养基和角质形成细胞(HaCaT)各100μl,培养24小时后换成无血清培养基。在无血清培养基中分别加入不同浓度各实施例及对比例(用去离子水进行稀释)的组合物24小时。之后去除培养基,用20μl的MTT溶液进行处理,在37℃下使其反应2小时。在去除MTT溶液的细胞中加入200μl异丙醇,轻轻地震荡30min,完全溶解结晶甲臜,在570nm处测定吸光度,根据如下公式计算细胞存活率。
表2实施例1-6、对比例1-2的细胞毒性结果
实验结果表明,本发明的组合物温和,没有细胞毒性。
细胞自噬实验实例
细胞自噬实验:在细胞自噬机制中,LC3溶于胞浆中,又称LC3-Ⅰ,LC3-Ⅰ被Atg7激活,转移至Atg3上,最终结合在PE上,形成LC3-PE,这种脂化的形式的LC3又称为LC3-Ⅱ,LC3-Ⅱ定位于在细胞自噬体上。LC3-Ⅱ在自噬体形成到自噬体与溶酶体结合的整个过程中始终存在,直到自噬体与溶酶体融合后才被溶酶体中的酸性水解酶降解,因此LC3-Ⅱ被公认为是监测自噬体和自噬活性的标志。
将表皮角质细胞(HaCaT)接种于含DK-SFM培养液的培养瓶中,置于37℃的CO2(CO2体积分数为5%)恒温培养箱中培养6d。将细胞培养瓶取出,在其中加入胰蛋白酶消化4min,然后将细胞接种于96孔板,孵育24h,对照组每孔加200μL细胞培养液,加药组每孔加200μL含1%wt实施例1-6组合物,对比例1组合物,阳性对照为1%wt海藻糖,培养箱中培养24h,检测LC3II蛋白的表达,结果重复三次取平均值。检测结果如图1所示。
实验结果表明:
(1)实施例1-6的组合物LC3II蛋白的表达率相比阳性对照海藻糖明显提高,说明组合物具有明显的细胞自噬效果;
(2)对比例2和实施例1-6说明粗齿绣球叶提取物具有细胞自噬效果,组合物中加入赖氨酸,LC3II蛋白的表达率提高,说明组合物中粗齿绣球叶和赖氨酸协同作用,可以提高细胞自噬活性;
(3)实施例1-6的组合物细胞自噬活性呈现先上升后变缓的趋势,说明组合物中的绣球叶提取物和赖氨酸的剂量关系影响自噬活性,综合功效、价格、稳定性等因素考虑,本发明优选例为实施例4。
细胞炎性因子抑制实例
单核细胞趋化蛋白-1(monocyte chemotactic protein 1,MCP-1)又称单核细胞趋化和激活因子,属于C-C亚族(β亚族)成员。单核细胞、巨噬细胞、成纤维细胞、内皮细胞、B细胞、平滑肌细胞等在PHA、LPS、Poly I-C、IL-1、IFN-γ、PDGF、EGF或某些病毒刺激下均可被诱导分泌MCP-1。前列腺素E2(prostaglandin E2,PGE-2)是由一种环氧合酶催化花生四烯酸产生的一种主要代谢产物,也是一种炎症因子,影响炎症反应。针对本发明优选例实施例4,检测1%质量浓度的实施例4组合物对于炎症因子MCP-1、PGE-2分泌是否具有抑制效果,用ELISA法检测空白组、脂多糖(LPS)诱导的HaCat细胞炎症反应后的模型组,用1μg/mlLPS刺激HaCat细胞后,将待测样品(10X)以每孔100μl加入12孔细胞板,于37℃5%CO2恒温培养箱培养72h。每个细胞板均设置阴性对照组(细胞+培养基),每个浓度组3个复孔。收集细胞培养上清,通过ELISA检测试剂盒进行炎性因子评价,测试结果见图2,图3。
实验结果表明,实施例4的组合物具有明显的舒缓LPS刺激PGE-2、MCP-1分泌的作用,说明本发明组合物具有良好的抑制炎症因子的作用。
剂型例1
一种包含粗齿绣球叶提取物的修复皮肤屏障抗衰老组合物的精华乳,成分如表3所示。
表3剂型例1的精华乳成分
上述包含粗齿绣球叶提取物的修复皮肤屏障抗衰老组合物的精华乳制备方法:
(1)将A相和B相分别加热到接近80℃,搅拌均匀;
(2)将A相加入到B相中,均质5-8分钟;
(3)加入C相,搅拌均匀,降温到30-50℃,加入D相,搅拌均匀,即得。
志愿者效果例1
筛选健康志愿者30名,年龄在35-45岁。使用剂型例1的精华乳,每天早晚各1次,连续使用4周,在使用前,使用两周使用四周后利用Tewameter测量经表皮失水率(TEWL),利用Tewameter测量皮肤血红素含量,利用Cutometer测试面部R2值(注:R2:无负压时皮肤的回弹量有有负压时的最大拉伸量之比,比值越接近1,说明皮肤弹力越好),测试结果见图4、图5、图6。
由实验结果可知,使用产品四周,皮肤的经表皮水分流失TEWL值降低了31%,血红素浓度下降了11.50%,皮肤回弹比R2增长17.86%,表明本发明的产品具有明显的降低红血丝修复皮肤屏障增强皮肤弹力的效果,本发明包含粗齿绣球叶提取物具有显著的抗炎修复皮肤屏障增强皮肤弹力的功效。
本领域的技术人员容易理解,以上所述仅为本发明的实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种包含粗齿绣球叶提取物的组合物,其特征在于,所述组合物中包含活性成分、促渗成分和溶剂,其中,所述活性成分和促渗成分的质量比为0.1-20:2-3,所述活性成分中包含粗齿绣球叶提取物和赖氨酸。
2.根据权利要求1所述的包含粗齿绣球叶提取物的组合物,其特征在于,所述粗齿绣球叶提取物的制备方法为:将粗齿绣球叶清洗分拣,干燥,加入2-3倍质量的溶剂超声粉碎匀浆,过滤,滤液浓缩至三分之一至五分之一即得。
3.根据权利要求1所述的包含粗齿绣球叶提取物的组合物,其特征在于,所述活性成分和促渗成分的质量比为0.1-10:2-3。
4.根据权利要求1所述的包含粗齿绣球叶提取物的组合物,其特征在于,所述活性成分中粗齿绣球叶提取物和赖氨酸的质量比为1-10:0.1-0.5;优选2-10:0.1-0.5;更优选5-10:0.2-0.5。
5.根据权利要求1所述的包含粗齿绣球叶提取物的组合物,其特征在于,所述促渗成分为1,2-戊二醇、1,2-己二醇和卵磷脂中的一种或多种;优选地,所述溶剂为去离子水、乙醇、丙二醇、丁二醇、双丙甘醇和甘油中的一种或多种。
6.权利要求1-5任一项所述包含粗齿绣球叶提取物的组合物的制备方法,其特征在于,所述方法包含以下步骤:
(1)将粗齿绣球叶清洗分拣,干燥,加入2-3倍溶剂超声粉碎匀浆,过滤,超声时间30-60min,频率40-80Hz,次数2-3次,合并滤液浓缩至三分之一至五分之一备用;
(2)在步骤(1)所得粗齿绣球叶提取物中加入赖氨酸、促渗成分和溶剂,加热搅拌均匀,过滤,再加入余量溶剂,搅拌均匀得到组合物,其中,粗齿绣球叶提取物和赖氨酸为活性成分。
7.根据权利要求6所述的包含粗齿绣球叶提取物的组合物的制备方法,其特征在于,所述步骤(2)中活性成分、促渗成分与溶剂的质量比为0.1-20:2-3:77-97;优选地,所述步骤(2)中加热搅拌前加入的溶剂和余量溶剂的质量比为35-45:32-62;优选地,所述步骤(1)中干燥为冷冻干燥;优选地,所述步骤(2)中过滤是用膜孔径为0.15-0.25微米的滤膜过滤。
8.权利要求1-5任一项所述包含粗齿绣球叶提取物的组合物的应用,其特征在于,所述应用为将包含粗齿绣球叶提取物的组合物用于制备诱导细胞自噬、降低/治疗炎症反应类病症的化妆品或药物。
9.根据权利要求8所述包含粗齿绣球叶提取物的组合物的应用,其特征在于,所述化妆品或药物为减少炎症因子分泌修复肌肤屏障的化妆品或药物;优选地,所述化妆品为水剂、乳剂、喷雾、膏霜、面膜、洁面泡沫、洁面慕斯、油液、粉饼、眼影或粉底液。
10.包含权利要求1-5任一项所述粗齿绣球叶提取物的组合物的精华乳,其特征在于,所述精华乳中还包含聚甘油-3二硬脂酸酯、硬脂酸乙基己酯、聚二甲基硅氧烷、硬脂酸、甘油、水、黄原胶、对羟基苯乙酮和丙烯酰二甲基牛磺酸铵/VP共聚物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111458306.8A CN114146032A (zh) | 2021-12-02 | 2021-12-02 | 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111458306.8A CN114146032A (zh) | 2021-12-02 | 2021-12-02 | 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114146032A true CN114146032A (zh) | 2022-03-08 |
Family
ID=80455568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111458306.8A Pending CN114146032A (zh) | 2021-12-02 | 2021-12-02 | 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114146032A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108403537A (zh) * | 2018-06-17 | 2018-08-17 | 佛山文森特知识产权服务有限公司 | 一种皮肤美白化妆品组合物及其应用 |
CN111315354A (zh) * | 2017-11-06 | 2020-06-19 | 株式会社爱茉莉太平洋 | 含有粗齿绣球提取物的用于皮肤抗老化及保湿的化妆料组合物 |
CN112156062A (zh) * | 2020-09-11 | 2021-01-01 | 铂臻(广州)生物科技有限公司 | 一种具有抗炎修复活性的组合物以及含有该组合物的精华液 |
CN113693955A (zh) * | 2020-10-09 | 2021-11-26 | 广州俏姿颜化妆品有限公司 | 一种精华液 |
-
2021
- 2021-12-02 CN CN202111458306.8A patent/CN114146032A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111315354A (zh) * | 2017-11-06 | 2020-06-19 | 株式会社爱茉莉太平洋 | 含有粗齿绣球提取物的用于皮肤抗老化及保湿的化妆料组合物 |
CN108403537A (zh) * | 2018-06-17 | 2018-08-17 | 佛山文森特知识产权服务有限公司 | 一种皮肤美白化妆品组合物及其应用 |
CN112156062A (zh) * | 2020-09-11 | 2021-01-01 | 铂臻(广州)生物科技有限公司 | 一种具有抗炎修复活性的组合物以及含有该组合物的精华液 |
CN113693955A (zh) * | 2020-10-09 | 2021-11-26 | 广州俏姿颜化妆品有限公司 | 一种精华液 |
Non-Patent Citations (2)
Title |
---|
佚名: "CEZANNE Skin Conditioner", Retrieved from the Internet <URL:https://www.cosdna.com/chs/cosmetic_a800276541.html> * |
张凤翔等: "现代实用美容学", 中国科学技术出版社, pages: 27 - 28 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8101214B2 (en) | Composition for skin external application containing complex of herbal extracts | |
KR101921211B1 (ko) | 단풍취 추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 재생용 화장료 조성물 | |
US9675650B2 (en) | Composition for removing keratinous skin material comprising green tea Lactobacillus | |
KR20100135871A (ko) | 섬유모세포의 증식 및/또는 활성을 자극하는 활성 성분 | |
JP7174736B2 (ja) | ダイダイの地上部の発酵抽出物 | |
CN111904919B (zh) | 一种除螨调理剂、沐浴露及其制备方法 | |
CN111317701A (zh) | 一种皮肤屏障修护复合物、护肤乳液及其制备方法 | |
CN111803422B (zh) | 一种控油组合物及其应用 | |
KR101863344B1 (ko) | 줄기세포의 무혈청 배양액을 유효성분으로 함유하는 피부 항노화용 화장료 조성물 | |
JP2024056871A (ja) | 毛髪化粧料 | |
CN108904436B (zh) | 一种兼具抗炎、抗老化作用的抗污染护肤组合物 | |
KR100309071B1 (ko) | 콜라겐합성촉진제를함유한피부용조성물 | |
CN113631227A (zh) | 抗老化剂、抗氧化剂、抗炎剂、及美白剂、以及化妆品 | |
CN114146032A (zh) | 一种包含粗齿绣球叶提取物的组合物及其制备方法和应用 | |
CN113384510B (zh) | 一种具有抗光老化、舒缓清凉功效的发酵组合物及其制备方法和应用 | |
CN103536710B (zh) | 白蔹提取物的制备方法及应用 | |
CN114948814A (zh) | 紫珠果提取物在制备抑制组胺生成的护肤品中的应用 | |
KR102003186B1 (ko) | 안디로바 오일 및 프라칵시 오일을 함유하는 화장료 조성물 및 그의 제조방법 | |
KR102027349B1 (ko) | 잎새버섯 다당체를 함유하는 피부 외용제 조성물 및 이의 제조 방법 | |
CN107550810B (zh) | 一种中药组合物及其制备方法和应用 | |
KR20100122967A (ko) | 피부 노화 방지용 화장료 조성물 | |
CN113350241B (zh) | 榄仁树叶提取物的用途、舒敏组合物及其应用 | |
KR102683428B1 (ko) | 피지, 피부 모공, 피부 각질 및 피부 여드름 개선용 화장료 조성물 | |
KR102446610B1 (ko) | 스코폴린, 스코폴레틴 및 진세노사이드가 증진된 인체세정용 조성물 및 이의 이용 | |
CN113456547B (zh) | 一种舒敏抗炎功效的护肤组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220308 |
|
RJ01 | Rejection of invention patent application after publication |